Mitsubishi Tanabe’s Edaravone Receives NMPA’s Approval for Amyotrophic Lateral Sclerosis (ALS)

Mitsubishi Tanabe’s Edaravone Receives NMPA’s Approval for Amyotrophic Lateral Sclerosis (ALS)

Shots:

  • Post MHLW approval in Japan in 2015, the company has received NMPA approval for Edaravone and is approved in six countries of China. Additionally, the product is approved in South Korea in Dec 2015, the US in May 2017, Canada in Oct 2018, and Switzerland
  • Mitsubishi Tanabe Pharma Development (Beijing) is an R&D firm of the subsidiary in China who filed it and Tianjin Tanabe Seiyaku is a manufacturer and sales subsidiary in China, will be responsible for the marketing of Edaravone
  • Edaravone is a free-radical scavenger marketed as Radicut in Japan, has an ability to scavenge free radicals arising accompanying cerebral ischemic, controlling the lipid peroxidation reactions, and protecting neurons in the region of the ischemia and the surrounding region

Click here to­ read full press release/ article | Ref: Mitsubishi Tanabe| Image: Chicago Tribune